Phase I/II Study of a Lentigen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult patients with relapsed/refractory CD19 Positive Non-Hodgkin’s Lymphoma (NHL) using a Closed Transduction System

drug protocol number
2191301
drug sponsor
King Faisal Specialist Hospital and Research Centre
drug study
CD19-CART
drug trial site
KFSH&RC-R
drug status
Completed
drug phase